

### AMENDMENTS TO THE CLAIMS

Please amend the claims, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, to read as follows:

1-3. (Cancelled)

4. (Currently Amended) A method of treating haemophilia A or haemophilia B, comprising administering by injection to a patient in need thereof a pharmaceutically effective amount of a sterile pharmaceutical composition consisting essentially of coagulation factors VIII and IXa, wherein the presence of coagulation factor IXa allows the concentration of coagulation factor VIII in the composition to be reduced in comparison to a composition which does not comprise a coagulation factor IXa, and wherein the sterile pharmaceutical composition is administered to a patient who does not present with anti-coagulation factor VIII antibodies.

5. (Cancelled)

6. (Previously Presented) The method according to claim 4, wherein the coagulation factor VIII and IXa reagents are produced using recombinant DNA technology.

7. (Previously Presented) The method according to claim 4, wherein the sterile pharmaceutical composition further comprises phospholipid.

8. (Previously Presented) The method according to claim 4, wherein the sterile pharmaceutical composition is formulated to provide coagulation factor VIII to a subject at a dosage of between 2 and 10 IU/kg.

9-22. (Cancelled)